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Abstract
Background: The population structure and drug resistance pattern of Mycobacterium tuberculosis complex (MTBC)
isolates in Ethiopian prisons and some communities is still unknown.
Methods: A comparative cross sectional study was conducted on 126 MTBC strains isolated from prisons and
communities in southwestern, southern and eastern Ethiopia. Phenotypic drug susceptibility testing was performed
with the MGIT960 system. Combined 24-loci Mycobacterium interspersed repetitive unit-variable number tandem
repeat and spacer oligonucleotide typing methods were used to study the MTBC population structure. The
obtained data from prisons and communities were compared using statistical tests and regression analysis.
Results: A diverse population structure with 11 different lineages and sub-lineages was identified. The
predominant strains were the recently described Ethiopia_H37Rv like (27.52%) and Ethiopia_3 (16.51%) with
equal lineage distribution between prisons and communities. 28.57% of prison strains and 31.82% of
community strains shared the identical genotype with at least one other strain. The multidrug-resistance
(MDR) prevalence of the community was 2.27% whereas that of prisons was 9.52%. The highest mono
resistance was seen against streptomycin (15.89%).
Conclusion: Tuberculosis in communities and prisons is caused by a variety of MTBC lineages with
predominance of local Ethiopian lineages. The increasing prevalence of MDR MTBC strains is alarming. These
findings suggest the need for new approaches for control of MDR tuberculosis in Ethiopia.
Keywords: TB genotypes, Drug resistance, TB in Ethiopia
Background
Despite recent achievements seen in the fight against tu-
berculosis (TB), it still remains a significant cause of
morbidity and mortality in Ethiopia [1]. This situation is
worsened by an increase in prevalence of multidrug-
resistant (MDR) Mycobacterium tuberculosis complex
(MTBC) strains, defined as resistance to at least the two
most powerful first line anti-tuberculosis drugs; isoniazid
(INH) and rifampicin (RIF) [2].
The recent TB drug resistance survey, conducted in
Ethiopia from 2011 to 2013, revealed an increase in
MDR-TB with a prevalence of 2.3% and 17.8% among
new and previously treated cases, respectively [3]. These
data indicate that MDR-TB has been becoming a signifi-
cant public health threat in the country. The occurrence
and transmission of MDR-TB in confined environment
like correctional facilities could further worsen the prob-
lem [4]. Due to the specific conditions found in prisons
such as crowded living conditions, a large number of
inmates could be infected and develop active TB disease
within a short period of time. Accordingly, TB incidence
and MDR rates in prisons have been found to be higher
compared to that reported in the general population in
several studies [5–7]. This is likely to have an impact
* Correspondence: solali2005@gmail.com; Solomon.ali@ju.edu.et
†Equal contributors
1College of Health sciences, Jimma University, P.O. Box 1368, Jimma city,
Ethiopia
4CIHLMU Center for International Health, Ludwig-Maximilians-Universität,
Munich, Germany
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Ali et al. BMC Infectious Diseases  (2016) 16:687 
DOI 10.1186/s12879-016-2041-x
also on the civilian population e.g., by direct transmission
via visits, prison staff or later spread in community after
release from prison [7, 8]. Importantly, latently infected
inmates may become a reservoir of MDR-TB and a threat
to the communities. In some studies performed to identify
the risk factors for TB in communities previous incarcer-
ation history was described as a risk factor [9, 10].
While a number of studies confirm that TB rates are
higher in prisons [7, 8, 11] little direct evidence about
strain diversity and population structure of M.tuberculosis
within prisons and the interaction of the prison setting
with the community e.g., by molecular epidemiological
studies is available [4, 12].
Increasing evidence suggests that the underlying
genetic diversity of the MTBC has a significant impact
on the pathogenicity and immunogenicity of individual
strains, thus, knowledge of the regional population struc-
ture linked with phenotypic data such as with the drug
resistance pattern could be relevant for the implementa-
tion of an effective TB control program tailored to specific
genotypes and local circumstances [13]. Further, mo-
lecular epidemiological studies have been instrumental
to define recent transmission dynamics in various
settings as well as to describe the local and global
population structure of the MTBC [13]. Modern mo-
lecular DNA fingerprinting methods like Mycobacterial
Interspersed Repetitive Unit-Variable Number Tandem
Repeats (MIRU-VNTRs) typing and spacer oligonucleotide
typing (spoligotyping) are highly suited to investigate both,
the population structure and transmission of the MTBC in
communities or special settings such as prisons [14].
To date, no molecular epidemiological studies have
been carried out to decipher MTBC strain diversity in
prisons in Ethiopia. Only few studies investigated the
population structure of MTBC strains in communities
of central and northwestern parts of the country by spoli-
gotyping. Due to the limited discriminatory power of this
method, however, these studies reported the “ill defined”
T linage as predominant strain [15–17]. There are two
studies in which the combined methods of MIRU-VNTR
and spoligotyping were applied, and in which Delhi/
CAS was the dominating MTBC lineage [18, 19].
These two studies included only the north-western
part of Ethiopia.
In order to contribute to a more comprehensive
knowledge on MTBC strain diversity in the whole of
Ethiopia, we conducted a pilot study to determine the
population structure and drug resistance pattern of
MTBC strains isolated from prisons and communities
of southwestern, southern and eastern Ethiopia by com-
bined application of MIRU-VNTR and spoligotyping. We
further investigated to which extent the isolated
strains were related to each other by the calculation
of clustering rates.
Methods
MTBC strain collection at prisons and hospitals
Ethiopia is administratively organized within nine re-
gional states and two federal cities. Oromia and
Southern Nations, Nationalities and Peoples Regional
State (SNNPRS) are among the three biggest regions with
a total population of approximately 31,294,992 and
17,359,008 respectively [20]. Harari is the smallest regional
state in Ethiopia with a population of about 210,000 [20].
Somali regional state and Dire Dawa city have a popula-
tion of 5,148,989 and 387,000 respectively [20]. These four
regional states and one city together cover an area where
almost 65% of the total Ethiopian population resides [20].
As per Federal Ministry of Health and Health Related
Indicators report of 2012/2013, TB incidence per 100,000
population in the studied regional states and city was be-
tween 258.6 (SNNPRS) and 274.7 (Dire Dawa City), re-
spectively, per year [21].
From January 2013 to December 2013, a cross-
sectional study on TB-prevalence and risk factors was
conducted in 13 zonal prisons in the following regional
states which are located in the Southern, South western
and Eastern part of Ethiopia: Oromia, Southern Nations
Nationalities and Peoples Regional State (SNNPRS) and
Harari. The MTBC strains which were isolated from the
sputum of symptomatic prisoners were included in this
study [7]. According to the Ethiopian prison system
organization, Oromia regional state had 37 (17 zonal
and 20 district) prisons, while SNNPRS had 23 (13 zonal
and 10 district) prisons. Harari regional state had only
one zonal prison [22]. Zonal administrative prisons are
the largest prisons in Ethiopian context. Most of the
inmates incarcerated in zonal prisons are originated
from the populations living in the respective zones.
Seven out of 17 and five out of 13 prisons were selected
like in a lottery from Oromia and SNNPRS, respectively,
while the only prison of Harari regional state was in-
cluded in the study. By this approach, ca. 35% of the
total prison population of the included regional states
was represented in this study. Briefly, we applied the
WHO questionnaire [23] to screen up 15.495 prison
inmates for the presence of TB symptoms. Two sputum
samples were collected from those inmates who fulfilled
the criteria for a person presumed to have TB. One
sample was processed for direct smear microscopy per-
formed at the prisons, the second sample was used for
MTBC culture performed in the Jimma University Myco-
bacteriology laboratory. Further details on study population,
methodology of sample processing and data collection as
well as research outcome have been described previously
by Ali et al. [7].
From August 2013 to December 2013, all MTBC
strains which were routinely collected from newly diag-
nosed, smear positive pulmonary TB patients diagnosed
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in Jimma, Nekemtie, Ambo, Yabelo, Mizan, Dire Dawa,
Harar and Jigjiga at ambulant health care centers or
hospitals were included in this study. One early morning
sputum was collected per patient and analyzed with
smear microscopy in TB laboratories which are linked to
hospitals in the above named cities which are located in
the regional states Oromia, SNNPRS, Harari, Somali
and Dire Dawa. All laboratory procedures were per-
formed by trained hospital staff. The remaining was
temporarily stored in a refrigerator until transportation
to the Jimma University Mycobacteriology Laboratory.
Socio-demographic and previous treatment history data
were extracted from the registration book of tubercu-
losis clinics in respective hospitals.
Laboratory methods
All sputum samples, from both prisoners and commu-
nity based TB patients, were cultivated on LJ (BBL™
Lowenstein-Jensen Medium) at Jimma University
Mycobacteriology Laboratory and afterwards trans-
ported to Research Center Borstel (RCB), Germany, for
further analysis. At RCB, the strains were first reacti-
vated on liquid mycobacterium growth indicator tube
system (MGIT) 960. Drug susceptibility testing (DST)
was performed using the MGIT SIRE kit at a critical
concentration of streptomycin (STM) 1 μg, INH 0.1 μg,
RIF 1 μg and ethambutol (EMB) 5 μg as previously de-
scribed by the manufacturer [24]. DNA was extracted
from all isolates for following molecular analyses, includ-
ing genotyping methods [18]. Spoligotyping and 24- loci
MIRU-VNTR analysis was performed as described previ-
ously [25, 26], for MIRU-VNTR typing customized kits
were used (Genoscreen, Lilli, France). Spoligotypes com-
mon to more than one strain were designated as shared
types (ST) and was assigned a shared international type
number (SIT) according to the updated version of the
international spoligotype database SpolDB4 [27]. MIRU-
VNTR profiles with double alleles at a single locus were
considered to represent heterogeneous populations of the
same strain, whereas those with double alleles at 2 or
more loci were considered to represent mixed infections
or to indicate cross-contamination.
Basic strain classification and MLVA MTBC 15–9
nomenclature assignment was done using the MIRU-
VNTRplus database [28, 29]. For the clustering analysis,
samples with complete spoligotyping and MIRU-24 results
were included. Cluster was defined as two or more MTBC
isolates sharing identical MIRU-24 and spoligotyping pat-
terns. Heterogeneous isolates with double alleles at only
one locus were included in the cluster analysis (both pat-
terns were compared). Isolates with no PCR amplicon at
only one locus were treated as missing data at the respect-
ive locus and also were included, whereas isolates lacking
amplicons at two or more loci were excluded [28, 30].
The molecular typing data was analyzed with the
Bionumerics software (version 7.5; Applied Maths,
Sint-Martens-Latem, Belgium) as recommended by
the manufacturer. A dendrogram was generated using
the unweighted pair group method with arithmetic
averages (UPGMA) based on the copy number of 24-
loci MIRU-VNTR. The UPGMA tree was further
processed using EvolView [31].
Statistical analysis
Data were analyzed by STATA software version 10.0. The
distribution of proportions of categorical variables were
compared using chi-square or Fisher’s exact test, were ap-
propriate. Logistic regression modeling was performed to
estimate the crude effect of several risk factors on cluster-
ing by comparing their association with unique isolates
versus clustered isolates. Those risk factors which were
significantly associated with clustering in the crude ana-
lysis were included in the multivariable regression model.
P-values <0.05 were considered as statistically significant.
Results
A total of 127 MTBC strains were initially isolated from
sputum specimens collected in prisons (24) and hospi-
tals (103). Out of these, 18 (14.17%) isolates were
excluded from the final analysis: ten strains could not be
reactivated in (liquid) culture, five isolates were mixed
infections and three isolates had repeatedly inconsistent
DST results.
The basic information on the 109 participants and
strains included in the final analysis are depicted in
Table 1. As expected, there was a significant gender differ-
ence between participants from prisons, where 90.48%
were male, and hospitals with 51.14% males (p < 0.001).
The mean age of the study subject was 29.03 (95% CI;
26.89, 31.2) with no significant difference between prison
inmates and hospital participants (t = 0.93). All 88 partici-
pants from hospitals and 17 out of 21 (80.95%) inmates
from prison had never received previous TB therapy.
MTBC strains from prison inmates were collected in
Oromia and Southern Nations, Nationalities and Peoples
Regional State (SNNPRS) regional states. TB isolates from
hospital patients were additionally collected in Somali
regional state and Dire Dawa city administration.
MTBC population structure
Based on combined 24-loci MIRU-VNTR and spoligotyp-
ing patterns all 109 isolates could be classified into 11
previously described lineages and sub-lineages. The major-
ity (27.52%) of the strains were Ethiopia_H37RV like,
followed by Ethiopia_3 (16.51%) and Delhi/CAS (16.51%)
(Table 1). Seventeen isolates (15.60%) were assigned to the
Euro-American Superlineage. One (0.92%) strain of the
Beijing lineage was found. There was no statistical
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difference observed between prison isolates and hos-
pital isolates in relation to strain diversity although
Haarlem, EAI, Lineage 7, X-type and Beijing lineage
were not isolated in prisons (p = 0.784) (Table 1).
The different lineages of the isolates are depicted in
a radial UPGMA tree based on MIRU-VNTR
analysis (Fig. 1).
The combined UPGMA tree including the Ethiopian
MTBC strains of this study and those of a previous
study performed by our group in the northwestern part
of the country [18] is presented in the online supple-
ment (Additional file 1: Figure S1). Interestingly, the
frequency of particular genotypes is variable if different
areas in the country are considered.
Table 1 Basic participant information and strain characteristics
Variable Prison, % (n/N) Hospital, % (n/N) p-value Total% (n/N)
Sex
Male 90.48(19/21) 51.14(45/88) 0.001 58.72(64/109)
Age
> 45 years 14.29(3/21) 7.95(7/88) 0.366 9.17(10/109)
Previous TB treatment
No 80.95(17/21) 100.00(88/88) NA
Regions
Oromia 33.33(7/21) 10.23(9/88) 14.68(16/109)
SNNPRS 66.67(14/21) 39.77(35/88) 44.95(49/109)
Dire Dawa – 11.36(10/88) 0.001 9.17(10/109)
Harar – 15.91(14/88) 12.84(14/109)
Somali – 22.70(20/88) 18.35(20/109)
Lineage
Delhi/CAS 14.29(3/21) 17.05(15/88) 16.51(18/109)
Ethiopia_H37Rv like 42.86(9/21) 23.86(21/88) 27.52(30/109)
Euro-American Superlineage 14.29(3/21) 15.91(14/88) 15.60(17/109)
LAM 4.76(1/21) 3.41(3/88) 3.67(4/109)
Ethiopia_3 19.05(4/21) 15.91(14/88) 16.51(18/109)
Haarlem – 9.09(8/88) 0.784 7.34(8/109)
Ural 4.76(1/21) 5.68(5/88) 5.50(6/109)
Lineage 7 – 3.41(3/88) 2.75(3/109)
EAI – 2.27(2/88) 1.83(2/109)
X-type – 2.27(2/88) 1.83(2/109)
Beijing – 1.14(1/88) 0.92(1/109)
Clustering
Yes 28.57(6/21) 31.82(28/88) 0.773 31.19(34/109)
Drug resistance
Streptomycina 20.00(4/20)c 14.94(13/87) 0.577 15.89(17/107)
Isoniazide 9.52(2/21)b 6.82(6/88) 0.669 7.34(8/109)
Rifampicin 9.52(2/21)b 4.55(4/88) 0.369 5.50(6/109)
Ethambutola 10.00(2/20)b 3.41(3/88) 0.205 4.63(5/108)
MDR-resistance 9.52(2/21)b 2.27(2/88) 0.112 3.67(4/109)
Any drug resistance 19.05(4/21)c 21.59(19/88) 0.797 21.10(23/109)
N = total number of strains isolated from prisons (21) and hospitals (88)
n = number of strains in the specific subgroup
NA = not applicable
anote missing values
bincludes one subject with TB in the past
cincludes two subjects with TB in the past
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Drug resistance profile
In total, 27 (24.77%) isolates were resistant to at least
one anti-tuberculosis drug (Table 1, Fig. 1). The highest
mono-resistance detected was against STM (15.89%),
followed by INH (7.34%), RIF (5.50%) and EMB (4.63%).
The overall MDR rate was 3.67% (4 out of 109). MDR-
prevalence among community isolates was 2.27% (2 out
of 88) whereas it was 9.52% in prison isolates (2 out of
21, with one isolate from an inmate with previous
history of TB) (p = 0.112) (Table 1).
Among identified lineages, 1 of 3 of Lineage 7
isolates, 11.11% (2 of 18) of Ethiopia_3 isolates and
5.56% (1 of 18) of Delhi/CAS isolates were MDR TB
strains (Table 2).
Cluster analysis
Based on 24 loci MIRU-VNTR and spoligotyping analysis
34 of 109 (31.2%) isolates were grouped into 12 different
clusters ranging from 2 to 8 strains in size, with the largest
cluster comprising 8 strains of the Ethiopian_3 lineage,
followed by Ethiopia_H37Rv like (7 strains) and Euro-
American Superlineage (6 strains) (Fig. 1 and Table 3).
Among strains isolated from prisons 28.57% were clus-
tered, which was not significantly different from the
Fig. 1 Radial UPGMA tree based on the copy numbers of MIRU-VNTR 24-loci. Inner circle: lineages and sub-lineages, (EAI - East African Indian, LAM -
Latin American Mediterranean, CAS - Central Asia). Small rectangles in the second circle: drug resistance pattern of the individual isolates (green - fully
susceptible, red - MDR, blue - resistant but not MDR). Small rectangles in the third circle: origin of the patient (green - community
participant, red - prisoner). Small rectangle in the fourth circle: clustering according to 24-loci MIRU-VNTR and spoligotyping pattern
analysis; isolates with identical genotyping profile are highlighted in same color. Outer circle: MLVA MTBC 15–9 code
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proportion (31.82%) of clustered strains collected in the
community, (p = 0.773) (Table 1). Two strains isolated
from prisoners were clustered with two strains from com-
munity members (Fig. 1). The remaining 75 isolates did
not share their 24 loci MIRU-VNTR and spoligotyping
patterns with any other isolate and are considered unique.
We analyzed potential risk factors for clustering in this
study and found that the region from where a strain was
collected and the lineage type were independently asso-
ciated with clustering of TB strains (Table 3). For ex-
ample the odds for clustering of TB strains from Somali
region were more than eight times higher compared to
those from Oromia region (Table 3). Further, lineages of
Ethiopia_3 and also Haarlem were significantly associ-
ated with clustering (Table 3). In this study, drug resist-
ance as well as demographic characteristics (age and
sex) was not a risk factor for clustering.
The combined cluster analysis of the isolates collected
in our current study and those of Tessema et al. showed
eight clusters comprising isolates from both studies
(Additional file 1: Figure S1). Those clusters were formed
by strains belonging to the Delhi/CAS, Ethiopian_H37Rv
like, Haarlem and Ethiopia_3 lineage.
Discussion
In this study, we analyzed the MTBC strain population
in prisons and communities of southern, southwest and
eastern Ethiopia using combined spoligotyping and
MIRU-VNTR typing methods. In agreement with results
of previous reports from Ethiopia we could also show a
high strain diversity in our study [19, 25, 32]. About 34%
of the MTBC strains analyzed are Ethiopian specific
Lineages and sub-lineages, Lineage 7, Ethiopia_H37Rv
like and Ethiopia_3, which were described recently and
have not yet been reported elsewhere [18, 19, 33].
Opposed to other studies conducted in northwest
Ethiopia Delhi/CAS was not the dominating lineage
[18, 19]. Tessema et al. hypothesized that the influx of
Indian and Chinese peoples to Ethiopia due to growing
business relations with Ethiopia introduced the Delhi/
CAS lineage in the country [18]. If this hypothesis was
true, the Delhi/CAS lineage dominancy might have
started from the center Addis Ababa and is now pro-
cessing to the periphery. This could explain why in
some remote areas investigated in this study, where a
relevant proportion of the population are still leading a
nomadic life style which is driven by the search for
water and grazing land for their cattle, not Delhi/CAS
but the Ethiopian lineages are still dominating.
Clustering is a marker of recent transmission [34, 35]
and knowing the clustering rate of TB strains that circu-
late in the community can help to evaluate the perform-
ance of TB control programs or to formulate new
control strategies. The overall clustering rate in this
study was 31.19% which was lower than the previously
reported 45.1% from Ethiopia [18]. On the other hand
our clustering rate is consistent with the 32% reported
for Amhara regional state study [19]. This data could
suggest that a relevant proportion of active TB cases
were due to reactivation of latent infection. Indeed, there
was a significant decline in TB prevalence observed in
Ethiopia in the past five years [36]. This decline in active
TB cases might have contributed to the lower clustering
rate seen in this study compared to older reports. The
cluster analysis of our strains collected in 2013 and
strains analyzed by Tessema et al. in 2009 revealed
several clusters, including strains from both studies,
indicating that some strains remain in the population
Table 2 Anti TB drug resistance and MDR pattern by lineages
Lineage (N = 109) STM n (%)b INH n (%)b RIF n (%)b EMB n (%)b MDR n (%)b
Delhi/CAS (18) 4(23.53) 1(5.56) 1(5.56) 1(5.56) 1(5.56)
Ethiopia_H37Rvlike (30) 2(6.90) 1(3.33) 0 0 0
Euro-American Superlineage (17) 4(23.53) 0 0 0 0
LAM(4) 0 0 0 0 0
Ethiopia_3 (18) 2(11.11) 2(11.11) 3(16.67) 2(11.11) 2(11.11)
Haarlem (8) 3(37.50) 0 0 0 0
Ural(6) 0 1(16.67) 0 0 0
Lineage 7(3) 2 2 1 2 1
EAI (2) 0 0 1 0 0
X-type (2) 0 1 0 0 0
Beijing (1) 0 0 0 0 0
Total (109)a 17/107(15.89) 8/109(7.34) 6/109(5.50) 5/108(4.63) 4/109(3.67)
N = total number of strains
n = number of strains in the specific subgroup
anote missing data for STM and EMB
bPercentage was calculated for those lineages with more than 5 strains
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and lead either to reactivation of a remote infection or
are effectively transmitted over a four years timeframe in
Ethiopia [18]. Interestingly, transmission rates of active
TB seemed to be higher in Somali regional state. Strains
from this regional state showed a significantly higher
clustering rate compared to other regional states. This
finding could be explained with the geographic context
of Somali regional state which is bounded by Djibouti,
Somalia and Kenya [37] where a free and intensive
movement of peoples living in the border areas might
have contributed to an ongoing TB transmission.
As there was no statistical difference between the clus-
tering rates in the communities (31.82%) and prisons
(28.57%), our data suggest that transmission rates are
not higher in prisons than in communities. This com-
parison, however, is hampered by the slightly different
Table 3 Geographical information, phylogenic lineage, drug resistance pattern, and their association with strain clustering
Variables Unique strains (n) Clustered strains (n) COR (95% CI) p-value* AOR (95% CI) p-value$
Regions
Oromia 14 2 1
SNNPRS 32 17 3.72(0.76,18.31) 0.11 6.19 (0.92,41.83) 0.06
Dire Dawa 7 3 3.00(0.40,22.30) 0.28 3.98(0.35,44.90) 0.26
Harar 11 3 1.91(0.27,13.50) 0.52 1.36(0.15,12.70) 0.79
Somali 11 9 5.73(1.02,32.10) 0.04 8.76(1.07,71.88) 0.04
Lineage
Delhi/CAS 14 4 1
Ethiopia_H37Rv like 23 7 1.07(0.26,4.31) 0.93 1.20(0.28,5.20) 0.81
Euro-American Superlineage 11 6 1.91(0.43,8.48) 0.40 1.76(0.37,8.41) 0.48
LAM 2 2 3.50(0.37,33.31) 0.28 5.46(0.46,64.04) 0.18
Ethiopia_3 8 10 4.38(1.03,18.63) 0.05 8.72(1.69,45.02) 0.01
Haarlem 3 5 5.83(0.95,35.72) 0.06 7.88(0.98,63.23) 0.05
Others 14 0 - -
Streptomycin
Resistant 13 4 1
Susceptible 61 29 1.55(0.46,5.150) 0.48 NA NA
Isoniazide
Resistant 7 1 1
Susceptible 68 33 3.39(0.40,28.76) 0.26 NA NA
Rifampicin
Resistant 5 1 1
Susceptible 70 33 2.36(0.26,20.98) 0.44 NA NA
Ethambutol
Resistant 4 1 1
Susceptible 70 33 1.89(0.20,17.54) 0.58 NA NA
MDR
Yes 3 1 1
No 72 33 1.37(0.14,13.72) 0.79 NA NA
Any resistance
Yes 19 4 1
No 56 30 2.54(0.79,8.16) 0.12 NA NA
n = numbers of clustered (i.e., isolates sharing identical MIRU-24 and spoligotyping patterns with at least one other isolate) or unique (i.e., isolates that do not
share their MIRU-24 and spoligotyping pattern with any other isolate) strains in each stratum
COR = crude odds ratio
AOR = adjusted odds ratio: significant variables in the crude analysis were adjusted for age, region and genotype
NA = not applicable
* = p-value for univariate regression model
$ = p-value for multivariate regression model
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study regions, the low number of MTBC strains isolated
from prison inmates and the different approaches and
coverage of MTBC strain collection in prisons and com-
munities. On the other hand we could show that MTBC
strains which were isolated in prisons build clusters with
strains collected from community members. This finding
could indicate that TB infection was acquired in the
community and developed later to active TB disease
under the specific conditions found in prisons. This
hypothesis is further supported by findings which were
previously published by our group [7]. In that specific
study, a contact with a TB case at home before incarcer-
ation was one of the strongest risk factors for active TB
disease in prison [7].
Despite the great achievements seen in Ethiopia to re-
duce overall TB prevalence [1], the control of MDR-TB
still seems a distant prospect. In this study we have ob-
served an MDR-TB prevalence in the community of 2.27%
which was consistent with the 2.3% of the Ethiopian
public health institute (EPHI) survey report performed in
year 2014 [3]. However, comparing our findings with 0.8%
seen in 2002 [38] and the 1.6% estimation of WHO in
2011 indicates that MDR-TB is increasing with alarming
rate through time [3, 39]. In prisons, the MDR TB preva-
lence (9.52%) and also the number of subjects with TB in
the past was higher than in communities, although, this
difference was not statistically significant in our ana-
lysis of a limited number of isolates. This result is
alarming since prisons may act as a reservoir for MDR-
TB in the country. The occurrence of a single MDR-TB
case in prison might have huge implications for prison
health and the community, considering bidirectional
communication between both.
This study has several limitations and the findings
should be interpreted with care. First, due to a relative
short study period, the number of MTBC isolates in this
study, specifically the number of strains from prisoners,
is lower than in other reports [18, 19]. Therefore, the
magnitude of clustering and also specific risk factors on
clustering, e.g., drug resistance, could have been un-
detected or underestimated. Second, only TB strains
from selected communities (which had access to a TB
laboratory located in neighboring hospitals) and prisons
(to which the investigators had permission to enter)
were included in the analysis. This fact could introduce
selection bias, especially as only characteristics of TB
strains from participants who had access to the health
system or who were inmates in the rather huge zonal
prisons could be studied. Third, clustering rates could
be imprecise and rather reflecting the spread of domin-
ant strains types but not recent transmission as not all
MTBC strains in the study areas were analyzed but only
those collected in the catchment area of large hospitals
and large prisons. Fourth, the rather cross-sectional
study approach in both prison and community settings
did not allow for the investigation of risk factors of TB
transmission in cases with an incubation period of more
than 12 or five months, respectively. Fifth, HIV test
results were not available for community based patients.
This hampered the analysis of the influence of HIV on
TB transmission and clustering. Finally, this pilot study
highlights the need to further investigate the drug re-
sistance, population structure and transmission dynam-
ics of TB in communities and prisons in Ethiopia as
well as the interaction of both groups in a larger and
prospective survey.
Conclusion
Our study provides first data on MTBC population
structure and drug resistance pattern of strains found in
Ethiopian prisons and in regional states of the country
which were not studied before. Our findings suggest that
TB is still not sufficiently controlled in specific, poten-
tially remote, areas of the country and highlight the need
for improved tools and new strategies aiming for MDR-
TB control, especially in prisons. The fact that TB
strains from prisoners are forming clusters with commu-
nity based TB strains is worth noting and stresses the
importance of the inclusion of prisons in strategies for
TB control in the whole of Ethiopia. Future studies of
sufficient duration and area-wide strain collection need
to be performed to improve our knowledge on risk fac-
tors for TB transmission in Ethiopia.
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